blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1052974

EP1052974 - PHARMACEUTICAL FORMULATION CONTAINING EPOTHILONE [Right-click to bookmark this link]
Former [2000/47]COMPOSITIONS CONTAINING ORGANIC COMPOUNDS
[2008/44]
StatusPatent revoked
Status updated on  17.04.2015
Database last updated on 18.11.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): ES		published on 12.08.2020  [2020/33]
Applicant(s)For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  NL  PT  SE 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
[2014/52]
Former [2009/21]For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  NL  PT  SE 
NOVARTIS AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
Former [2003/11]For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  NL  PT  SE 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
Former [2003/10]For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  NL  PT  SE 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1235 Vienna / AT
Former [2001/32]For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  NL  PT  SE 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
Brunner Strasse 59
1235 Wien / AT
Former [2000/47]For:BE  CH  CY  DE  DK  ES  FI  FR  GB  GR  IE  IT  LI  LU  NL  PT  SE 
Novartis AG
Schwarzwaldallee 215
4058 Basel / CH
For:AT 
Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
Brunner Strasse 59
1235 Wien / AT
Inventor(s)01 / VAN HOOGEVEST, Peter
Breitenstrasse 3
CH-4416 Bubendorf / CH
[2000/47]
Representative(s)Breuer, Markus, et al
Henkel, Breuer & Partner
Patentanwälte
Erika-Mann-Straße 23
80636 München / DE
[N/P]
Former [2011/44]Henkel, Breuer & Partner
Patentanwälte
Erika-Mann Strasse 23
80636 München / DE
Former [2010/33]Breuer, Markus, et al
Breuer & Müller Partnerschaft Patentanwälte Heimeranstrasse 35
80339 München / DE
Former [2005/12]de Weerd, Petrus G.W., et al
Novartis International AG Corporate Intellectual Property
4002 Basel / CH
Former [2003/20]Grubb, Philip William, et al
Novartis AG, Corporate Intellectual Property, Lichtstrasse 35
4002 Basel / CH
Former [2000/47]Becker, Konrad, et al
Novartis AG, Corporate Intellectual Property, Patent- und Trademark Department
4002 Basel / CH
Application number, filing date99907491.703.02.1999
[2000/47]
WO1999EP00702
Priority number, dateGB1998000245105.02.1998         Original published format: GB 9802451
GB1998001364624.06.1998         Original published format: GB 9813646
[2000/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO9939694
Date:12.08.1999
Language:EN
[1999/32]
Type: A2 Application without search report 
No.:EP1052974
Date:22.11.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 12.08.1999 takes the place of the publication of the European patent application.
[2000/47]
Type: B1 Patent specification 
No.:EP1052974
Date:20.05.2009
Language:EN
[2009/21]
Search report(s)International search report - published on:EP23.09.1999
ClassificationIPC:A61K9/08, A61K9/19, A61K47/10, A61K47/18, A61K31/335, A61K31/365
[2000/47]
CPC:
A61K31/427 (EP,US); A61K9/08 (KR); A61K31/724 (EP,US);
A61K47/10 (EP,US); A61K47/26 (EP,US); A61K47/40 (EP,US);
A61K9/0019 (EP,US); A61K9/19 (EP,US); A61P35/00 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [2000/47]
Extension statesRO24.07.2000
SI24.07.2000
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EPOTHILONE[2008/44]
English:PHARMACEUTICAL FORMULATION CONTAINING EPOTHILONE[2008/44]
French:COMPOSITION PHARMACEUTIQUE CONTENANT DE L'EPOTHILONE[2008/44]
Former [2000/47]ARZNEIMITTEL ENTHALTEND ORGANISCHE VERBINDUNGEN
Former [2000/47]COMPOSITIONS CONTAINING ORGANIC COMPOUNDS
Former [2000/47]COMPOSITIONS CONTENANT DES COMPOSES ORGANIQUES
Entry into regional phase24.07.2000National basic fee paid 
24.07.2000Designation fee(s) paid 
24.07.2000Examination fee paid 
Examination procedure30.08.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
24.07.2000Examination requested  [2000/47]
20.10.2005Despatch of a communication from the examining division (Time limit: M04)
22.02.2006Reply to a communication from the examining division
02.10.2006Observations by third parties
08.11.2006Despatch of communication that the application is refused, reason: substantive examination {1}
19.11.2008Communication of intention to grant the patent
06.03.2009Fee for grant paid
06.03.2009Fee for publishing/printing paid
Appeal following examination05.01.2007Appeal received No.  T0064/07
05.01.2007Statement of grounds filed
01.02.2008Result of appeal procedure: continuation of examination procedure
Divisional application(s)EP07102856.7  / EP1800664
Opposition(s)Opponent(s)01  05.01.2010  21.01.2010  ADMISSIBLE
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton NJ 08543-4000 / US
Opponents representative
Wolter, Thomas, et al, et al
Reitstötter Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München / DE
 02  19.02.2010  02.03.2010  ADMISSIBLE
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
 [N/P]
Former [2011/43]
Opponent(s)01  05.01.2010  21.01.2010  ADMISSIBLE
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton NJ 08543-4000 / US
Opponents representative
Wolter, Thomas, et al, et al
Reitstötter, Kinzebach & Partner (GbR) Patentanwälte Postfach 86 06 49
81633 München / DE
 02  19.02.2010  02.03.2010  ADMISSIBLE
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
Former [2010/13]
Opponent(s)01  05.01.2010  21.01.2010  ADMISSIBLE
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton NJ 08543-4000 / US
Opponents representative
Wolter, Thomas, et al, et al
Reitstötter, Kinzebach & Partner (GbR) Patentanwälte Postfach 86 06 49
81633 München / DE
 02  19.02.2010   
Bayer Schering Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
Former [2010/08]
Opponent(s)01  05.01.2010  21.01.2010  ADMISSIBLE
Bristol-Myers Squibb Company
P.O. Box 4000
Princeton NJ 08543-4000 / US
Opponents representative
Wolter, Thomas, et al, et al
Reitstötter, Kinzebach & Partner (GbR) Patentanwälte Postfach 86 06 49
81633 München / DE
26.03.2010Invitation to proprietor to file observations on the notice of opposition
01.12.2010Reply of patent proprietor to notice(s) of opposition
24.11.2011Date of oral proceedings
09.02.2012Despatch of interlocutory decision in opposition
09.02.2012Despatch of minutes of oral proceedings
02.03.2015Despatch of communication that the patent will be revoked
12.03.2015Legal effect of revocation of patent [ N /P ]
12.03.2015Legal effect of revocation of patent [2015/21]
Appeal following opposition19.04.2012Appeal received No.  T0958/12
19.06.2012Statement of grounds filed
24.02.2015Result of appeal procedure: revocation of the patent
Fees paidRenewal fee
02.01.2001Renewal fee patent year 03
14.01.2002Renewal fee patent year 04
28.02.2003Renewal fee patent year 05
01.03.2004Renewal fee patent year 06
28.02.2005Renewal fee patent year 07
28.02.2006Renewal fee patent year 08
28.02.2007Renewal fee patent year 09
13.02.2008Renewal fee patent year 10
13.02.2009Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCH20.05.2009
LI20.05.2009
AT03.02.2015
CY03.02.2015
IT03.02.2015
ES04.02.2015
BE28.02.2015
[2020/33]
Former [2016/03]CH20.05.2009
LI20.05.2009
AT03.02.2015
CY03.02.2015
IT03.02.2015
BE28.02.2015
Former [2015/51]CH20.05.2009
LI20.05.2009
AT03.02.2015
CY03.02.2015
BE28.02.2015
Former [2015/48]CH20.05.2009
LI20.05.2009
CY03.02.2015
BE28.02.2015
Former [2015/33]CH20.05.2009
LI20.05.2009
BE28.02.2015
Former [2015/30]BE28.02.2015
Cited inInternational search[AD]WO9310121  (BIOTECHNOLOG FORSCHUNG GMBH [DE], et al) [AD] 1-19 * claims 1,8 *;
 [AD]WO9719086  (BIOTECHNOLOG FORSCHUNG GMBH [DE], et al) [AD] 1-19 * claims 1,13 *;
 [A]WO9733552  (WALLACE TECH INC [US], et al) [A] 1-19 * claims 1,12,21,26 ** page 16, line 30 - page 17, line 27 *
other   - Fiedler Lexikon der Hilfsstoffe, EDITIO CANTOR VERLAG, pages 857 - 859, XP003000138
    - Nonionic surfectants, vol. 1, pages 607 - 608, XP003000139
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.